Literature DB >> 30176494

Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?

Jeffrey R Vittengl1, Lee Anna Clark2, Jasper A J Smits3, Michael E Thase4, Robin B Jarrett5.   

Abstract

BACKGROUND: Cognitive therapy (CT) improves symptoms in adults with major depressive disorder (MDD) plus comorbid anxiety disorder, but the specific type of anxiety may influence outcomes. This study compared CT outcomes among adults with MDD plus social, other, or no comorbid anxiety disorders.
METHODS: Outpatients with recurrent MDD (N = 523, including 87 with social and 110 with other comorbid anxiety disorders) received acute-phase CT. Higher risk responders (n = 241 with partial or unstable response) were randomized to 8 months of continuation treatment (CT or clinical management plus fluoxetine or pill placebo), followed by 24 months of assessment. Lower risk responders (n = 49) were assessed for 32 months without additional research treatment. Depression, anxiety symptoms, and social avoidance were measured repeatedly.
RESULTS: Other (non-social), but not social, anxiety disorders predicted elevated depression and anxiety symptoms throughout and after acute-phase CT. Social, but not other, anxiety disorder predicted greater reduction in depressive symptoms during acute-phase CT and elevated social avoidance during and after acute-phase CT. LIMITATIONS: Anxiety disorders were assessed only before acute-phase treatment. The anxiety symptom measure was brief. Generalization to other patient populations and treatments is unknown.
CONCLUSIONS: Non-social comorbid anxiety disorders may reduce the efficacy of acute-phase CT for MDD by diminishing both short- and longer term outcomes relative to depressed patients without comorbid anxiety disorders. Comorbid social anxiety disorder may increase relative reductions in depressive symptoms during acute-phase CT for MDD, but patients with comorbid social anxiety disorder may require specialized focus on social avoidance during CT.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Anxiety disorders; Cognitive therapy; Comorbidity; Fluoxetine; Major depressive disorder; Social anxiety disorder

Mesh:

Substances:

Year:  2018        PMID: 30176494      PMCID: PMC6151272          DOI: 10.1016/j.jad.2018.08.053

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  46 in total

1.  Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.

Authors:  Robin B Jarrett; Michael E Thase
Journal:  Contemp Clin Trials       Date:  2010-05-06       Impact factor: 2.226

2.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal.

Authors:  T A Brown; B F Chorpita; D H Barlow
Journal:  J Abnorm Psychol       Date:  1998-05

4.  Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.

Authors:  Robin B Jarrett; Abu Minhajuddin; Howard Gershenfeld; Edward S Friedman; Michael E Thase
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

5.  Disorder-specific versus transdiagnostic and clinician-guided versus self-guided treatment for major depressive disorder and comorbid anxiety disorders: A randomized controlled trial.

Authors:  N Titov; B F Dear; L G Staples; M D Terides; E Karin; J Sheehan; L Johnston; M Gandy; V J Fogliati; B M Wootton; P M McEvoy
Journal:  J Anxiety Disord       Date:  2015-08-31

6.  Change in psychosocial functioning and depressive symptoms during acute-phase cognitive therapy for depression.

Authors:  T W Dunn; J R Vittengl; L A Clark; T Carmody; M E Thase; R B Jarrett
Journal:  Psychol Med       Date:  2011-07-25       Impact factor: 7.723

7.  Treating co-occurring depression and anxiety: modeling the dynamics of psychopathology and psychotherapy using the time-varying effect model.

Authors:  Aidan G C Wright; Michael N Hallquist; Holly A Swartz; Ellen Frank; Jill M Cyranowski
Journal:  J Consult Clin Psychol       Date:  2013-09-16

8.  Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.

Authors:  Robin B Jarrett; Abu Minhajuddin; Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase
Journal:  J Consult Clin Psychol       Date:  2015-12-14

Review 9.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

10.  The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies.

Authors:  M B Keller; P W Lavori; B Friedman; E Nielsen; J Endicott; P McDonald-Scott; N C Andreasen
Journal:  Arch Gen Psychiatry       Date:  1987-06
View more
  2 in total

1.  Does the therapist matter? Therapist characteristics and their relation to outcome in trauma-focused cognitive behavioral therapy for children and adolescents.

Authors:  Elisa Pfeiffer; Silje Mørup Ormhaug; Dunja Tutus; Tonje Holt; Rita Rosner; Tore Wentzel Larsen; Tine K Jensen
Journal:  Eur J Psychotraumatol       Date:  2020-07-23

2.  Evaluation of Changes in Depression, Anxiety, and Social Anxiety Using Smartphone Sensor Features: Longitudinal Cohort Study.

Authors:  Jonah Meyerhoff; Tony Liu; Konrad P Kording; Lyle H Ungar; Susan M Kaiser; Chris J Karr; David C Mohr
Journal:  J Med Internet Res       Date:  2021-09-03       Impact factor: 5.428

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.